Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double-blind, Randomized, Placebo Controlled, Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301), in Patients With Severe Traumatic Brain Injury (TBI).

NCT06253923 is registered in ClinicalTrials.gov with SHINKEI Therapeutics, Inc as lead sponsor.

NCT NCT06253923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06253923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double-blind, Randomized, Placebo Controlled, Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301), in Patients With Severe Traumatic Brain Injury (TBI).
Lead sponsor
SHINKEI Therapeutics, Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 1, 2024
Completion date
August 31, 2025
Enrollment
45 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

traumatic brain injury